Pei Wang | Mount Sinai

Biography

Dr. Wang is a Professor of Genetics and Genomic Sciences. She received her Ph.D. in Statistics from Stanford University in 2004. Between 2004-2013, she served as a faculty in Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA. In Oct 2013, Dr. Wang joined the faculty of Icahn School of Medicine at Mount Sinai's Department of Genetics and Genomics. Dr. Wang’s research work has been focused on developing statistical and computational methods to address scientific questions based on data from high throughput biology/genetics experiments. Dr. Wang is a member of the Icahn Genomics Institute.

Research

High dimensional inference & integrative genomics

I am interested in developing statistical and computational methods to address scientific questions based on data from high throughput biology/genetics experiments. The ultimate goal is to enhance our understanding of cell activities and disease initiation/progression to a system level by integrating information from diverse biological sources (genetics/genomics, proteomics, and phenotypes). Towards this goal, efforts have been made to properly model each individual type of data and to effectively characterize interactions among different biology molecules. These efforts all borrow strength from and contribute to the developments of high dimensional inference, a challenging yet thriving field in modern statistics. For more details about Dr. Wang’s research, visit http://research.mssm.edu/wanglab/

Education

BS, Peking University

PhD, Stanford University

Publications

197

Publications

Selected Publications

Rbm39 ameliorates metabolic dysfunction-associated steatotic liver disease by regulating Apob and Fabp4. Chunbo Zhuang, Fangfang Cui, Jin Chen, Dezhi He, Ting Sun, Pei Wang. Biochimica et Biophysica Acta - Molecular Basis of Disease

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups. Shunrong Ji, Lihua Cao, Jing Gao, Yang Du, Zeng Ye, Xin Lou, Fen Liu, Yehan Zhang, Junfeng Xu, Xiaohan Shi, Huan Wang, Penghao Li, Yikai Li, Hongxu Chen, Zhicheng Yang, Suizhi Gao, Wuhu Zhang, Dan Huang, Shujuan Ni, Miaoyan Wei, Fei Wang, Yan Wang, Tian Ding, Desheng Jing, Guixiong Fan, Zhiyun Gong, Renquan Lu, Yi Qin, Jie Chen, Xiaowu Xu, Pei Wang, Bing Zhang, Li Ding, Ana I. Robles, Henry Rodriguez, David K. Chang, Ralph H. Hruban, Dong Gao, Daming Gao, Gang Jin, Hu Zhou, Jianmin Wu, Xianjun Yu. Cancer Cell

Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer. Shrabanti Chowdhury, Sammy Ferri-Borgogno, Peng Yang, Wenyi Wang, Jie Peng, Samuel C. Mok, Pei Wang. Briefings in Bioinformatics

View All Publications

Office Locations

Genetics & Genomics Floor 14 Room 1415

770 Lexington Ave

New York, NY 10065

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Wang did not report having any of the following types of financial relationships with industry and other outside entities during 2024 and/or 2025: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Wang did not report having any of the following types of financial relationships with industry and other outside entities during 2024 and/or 2025: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.